Tyra Biosciences (TYRA) Stock Forecast & Price Target

Tyra Biosciences is expected to have positive results for its drug candidate, Dabogratinib, in the treatment of bladder and skeletal dysplasia. With a Buy rating and potential for a $45 per share price target, analysts have high hopes for this targeted FGFR3 inhibitor. The potential for dabogratinib to be successful in other diseases caused by FGFR3 mutations, coupled with promising results in reducing tumor recurrence and off-target toxicities, makes it a promising investment opportunity.

Tyra Biosciences is a clinical stage biotech company with a potential market opportunity of over $5 billion. However, their drug, dabogratinib, has shown off-target toxicity at high doses and lower doses may not be as effective. The company must successfully demonstrate a best-in-class profile for dabogratinib in order to achieve success in their three targeted indications. Risks for the company include operational issues, competitive dosing, safety concerns, and the emergence of new competitors. Given the limited data available and the potential for failure in their upcoming data catalysts, there is a significant amount of risk associated with Tyra Biosciences and their stock may be overvalued.